Search Results

Cytovale® announced that the first hospital to commercially implement the company’s IntelliSep® rapid sepsis diagnostic has now screened over 5,000 patients with the test.

Cytovale today announced the appointment of Christopher Slachta, Ph.D., MBA, as the company’s chief operating officer (COO).

Cytovale® announced the publication of a new peer reviewed-study in “Academic Emergency Medicine’’ that demonstrates strong diagnostic performance of the company’s IntelliSep® host response test for sepsis detection.

Cytovale® announced new data that demonstrates how its IntelliSep® test reduced cost of care and improved efficiency of sepsis care for a large U.S. academic center.

Cytovale® announced it has raised $84 million in Series C funding led by Norwest Venture Partners with participation by additional new investors Sands Capital and Global Health Investment Corporation.

Cytovale ® Announces Commercial Launch of IntelliSep ® Sepsis Test, the First-of-its-Kind Diagnostic Tool for Emergency Departments.

Cytovale®, a pioneering medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, announced that newly presented data for its IntelliSep® test further reinforce its potential to aid in rapid, clinically actionable sepsis diagnoses in emergency departments.

Cytovale® announced today that its IntelliSep® test has received U.S. Food and Drug Administration (FDA) 510(k) clearance to aid in the early detection of sepsis for the approximately 30 million adult patients with signs and symptoms of infection who present to US emergency departments (ED) each year.

Cytovale ® , a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, will reveal its 510(k) pending Cytovale system and 10-minute IntelliSep ® sepsis risk stratification test at the American Association for Clinical Chemistry (AACC) annual meeting.